Canaccord analyst Richard Close lowered the firm’s price target on Doximity (DOCS) to $48 from $58 and keeps a Hold rating on the shares. The firm updated its model to reflect an uncertain healthcare spending environment.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target raised to $50 from $48 at Canaccord
- Doximity: Compelling Long Opportunity Amid Overdone Competitive Fears and Undervalued AI-Driven Growth
- Doximity Reaches Proposed Settlement in Securities Litigation Case
- Doximity to settle securities litigation lawsuit for $31M
- Doximity: Physicians-First Platform With Durable Moat and High Margins Offers Attractive Long-Term Entry Point